Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients' blood.
Orcutt-Jahns B, Junior JRL, Rockne RC, Matache A, Branciamore S, Hung E, Rodin AS, Lee PP, Meyer AS. Orcutt-Jahns B, et al. Among authors: lee pp. bioRxiv [Preprint]. 2023 Nov 3:2023.10.31.564987. doi: 10.1101/2023.10.31.564987. bioRxiv. 2023. Update in: NPJ Syst Biol Appl. 2024 Oct 10;10(1):118. doi: 10.1038/s41540-024-00447-0 PMID: 37961682 Free PMC article. Updated. Preprint.
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y. Egelston CA, et al. Among authors: lee js, lee pp. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. Cancer Immunol Immunother. 2023. PMID: 37294342 Free PMC article. Clinical Trial.
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S, Budde LE, Armenian S, Nikolaenko L, Nwangwu M, Guo W, Gao L, Lee P, Chen R, Daniels S, Kennedy N, Peters L, Zain J, Rosen S, Forman S, Popplewell L, Kwak L, Herrera AF. Mei M, et al. Blood. 2023 Oct 19;142(16):1359-1370. doi: 10.1182/blood.2023020485. Blood. 2023. PMID: 37339586 Free PMC article.
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Herrera AF, et al. Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17. Lancet Haematol. 2023. PMID: 36403579 Clinical Trial.
635 results